Sagent Pharmaceuticals, Inc. (SGNT) Posts Q3 Loss of $0.17, Sales Top Expectations

Article Stock Quotes (1) Comments (0)

Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) reported Q3 EPS of ($0.17), $0.05 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $41.3 million versus the consensus estimate of $40.97 million.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Hewlett-Packard Company (HPQ) Tops Q2 EPS by 6c as Sales Slide 10%
• Semtech Corp (SMTC) Reports In-Line Q1 EPS, Offers Q2 Guidance
• NetApp (NTAP) Tops Q4 EPS by 1c; Boosts Buyback, Plans Job Cuts, Initiates Dividend

Create E-mail Alert Related Categories

Earnings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?